Erik Fink Eriksen is a Professor of Endocrinology at the University of Oslo. With 22 years of clinical medical and research experience in Internal medicine and Endocrinology, in particular calcium metabolic- and osteoporosis research. He was a consultant for several pharmaceutical companies (Procter & Gamble, Rhone Poulenc Rorer, Novo-Nordisk, Glaxo–Smith Kline, Merck) during that period. Over 6 years of experience as manager in the pharmaceutical industry, where he have taken two successful osteoporosis drugs (For(s)teo and Aclasta/Reclast) through clinical development, approval by regulatory authorities and global launch. Extensive experience in basic and clinical research within calcium metabolism and osteoporosis (>250 publications). My goal is to provide new solutions to unmet medical needs and expand our general knowledge in relation to musculoskeletal diseases.
Specialties: Clinical drug development, conduct and development of clinical trials, basic cellular and molecular research methodology, medical-marketing interactions, extensive clinical medical experience within internal medicine and endocrinology.